QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
NASDAQ:ORTX

Orchard Therapeutics (ORTX) Stock Forecast, Price & News

$4.80
-0.11 (-2.24%)
(As of 05/31/2023 ET)
Compare
Today's Range
$4.80
$4.96
50-Day Range
$4.68
$5.83
52-Week Range
$3.60
$7.20
Volume
30,695 shs
Average Volume
91,728 shs
Market Capitalization
$88.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.00

Orchard Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
441.7% Upside
$26.00 Price Target
Short Interest
Healthy
0.46% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.24mentions of Orchard Therapeutics in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.96) to ($2.99) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.42 out of 5 stars

Medical Sector

213th out of 1,006 stocks

Biological Products, Except Diagnostic Industry

29th out of 167 stocks


ORTX stock logo

About Orchard Therapeutics (NASDAQ:ORTX) Stock

Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom.

Receive ORTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Orchard Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ORTX Stock News Headlines

66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Orchard Beach non-stop busy for Memorial Day
Plans for Orchard Mesa Pool
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Two people suffer cuts in Old Orchard Beach
See More Headlines
Receive ORTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Orchard Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ORTX Company Calendar

Last Earnings
5/15/2023
Today
5/31/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ORTX
Fax
N/A
Employees
259
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$26.00
High Stock Price Forecast
$37.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+439.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-150,660,000.00
Net Margins
-673.87%
Pretax Margin
-687.17%

Debt

Sales & Book Value

Annual Sales
$22.66 million
Book Value
$5.53 per share

Miscellaneous

Free Float
17,784,000
Market Cap
$88.69 million
Optionable
Not Optionable
Beta
0.91

Key Executives

  • Bobby Gaspar
    Chief Executive Officer & Executive Director
  • Frank E. Thomas
    President, Chief Operating Officer & CFO
  • Leslie Meltzer
    Chief Medical Officer
  • Nicoletta Loggia
    Chief Technical Officer
  • Fulvio Mavilio
    Chief Scientific Officer













ORTX Stock - Frequently Asked Questions

Should I buy or sell Orchard Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Orchard Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ORTX shares.
View ORTX analyst ratings
or view top-rated stocks.

What is Orchard Therapeutics' stock price forecast for 2023?

1 brokers have issued 1-year price targets for Orchard Therapeutics' stock. Their ORTX share price forecasts range from $15.00 to $37.00. On average, they anticipate the company's stock price to reach $26.00 in the next year. This suggests a possible upside of 439.4% from the stock's current price.
View analysts price targets for ORTX
or view top-rated stocks among Wall Street analysts.

How have ORTX shares performed in 2023?

Orchard Therapeutics' stock was trading at $3.71 at the start of the year. Since then, ORTX shares have increased by 29.9% and is now trading at $4.82.
View the best growth stocks for 2023 here
.

Are investors shorting Orchard Therapeutics?

Orchard Therapeutics saw a decline in short interest in May. As of May 15th, there was short interest totaling 80,600 shares, a decline of 25.4% from the April 30th total of 108,100 shares. Based on an average daily trading volume, of 72,600 shares, the days-to-cover ratio is presently 1.1 days. Currently, 0.5% of the company's stock are short sold.
View Orchard Therapeutics' Short Interest
.

When is Orchard Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our ORTX earnings forecast
.

How were Orchard Therapeutics' earnings last quarter?

Orchard Therapeutics plc (NASDAQ:ORTX) issued its earnings results on Monday, May, 15th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.61) by $1.49. The firm earned $1.24 million during the quarter, compared to the consensus estimate of $6.48 million. Orchard Therapeutics had a negative trailing twelve-month return on equity of 105.36% and a negative net margin of 673.87%.

When did Orchard Therapeutics' stock split?

Shares of Orchard Therapeutics reverse split on the morning of Friday, March 10th 2023. The 1-10 reverse split was announced on Friday, March 10th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Orchard Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Orchard Therapeutics investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Corbus Pharmaceuticals (CRBP), Entasis Therapeutics (ETTX), Selecta Biosciences (SELB) and VBI Vaccines (VBIV).

When did Orchard Therapeutics IPO?

(ORTX) raised $200 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 13,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Orchard Therapeutics' stock symbol?

Orchard Therapeutics trades on the NASDAQ under the ticker symbol "ORTX."

Who are Orchard Therapeutics' major shareholders?

Orchard Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Federated Hermes Inc. (10.46%), CHI Advisors LLC (4.27%), Temasek Holdings Private Ltd (2.35%), Citigroup Inc. (0.91%), Acadian Asset Management LLC (0.65%) and Platinum Investment Management Ltd. (0.65%). Insiders that own company stock include Bobby Gaspar, Fmr Llc and Frank E Thomas.
View institutional ownership trends
.

How do I buy shares of Orchard Therapeutics?

Shares of ORTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Orchard Therapeutics' stock price today?

One share of ORTX stock can currently be purchased for approximately $4.82.

How much money does Orchard Therapeutics make?

Orchard Therapeutics (NASDAQ:ORTX) has a market capitalization of $88.69 million and generates $22.66 million in revenue each year. The company earns $-150,660,000.00 in net income (profit) each year or ($8.42) on an earnings per share basis.

How many employees does Orchard Therapeutics have?

The company employs 259 workers across the globe.

How can I contact Orchard Therapeutics?

Orchard Therapeutics' mailing address is 108 CANNON STREET, LONDON X0, EC4N 6EU. The official website for the company is www.orchard-tx.com. The company can be reached via phone at 442038088286 or via email at investors@orchard-tx.com.

This page (NASDAQ:ORTX) was last updated on 5/31/2023 by MarketBeat.com Staff

My Account -